Loading...
Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age
The kinase inhibitor sorafenib is the only systemic therapy proven to have a positive effect on survival of patients with advanced hepatocellular carcinoma (HCC). After development of sorafenib and its introduction as a therapeutic agent used in the clinic, several critical questions have been raise...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Baishideng Publishing Group Co., Limited
2014
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3989951/ https://ncbi.nlm.nih.gov/pubmed/24764653 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v20.i15.4151 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|